Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment

European Neurology

Volumn 38, Issue 4, 1997, Pages 284-290

  Cavazzuti, Milena ^a   Merelli, Elisa ^a   Tassone, Giuseppe ^a   Mavilla, Luciano ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Azathioprine; Lesion load; MRI; Multiple sclerosis; Quantitative assessment

Indexed keywords

AZATHIOPRINE; STEROID;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RATING SCALE; RETROSPECTIVE STUDY;

ADULT; AZATHIOPRINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; RECURRENCE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 0030669344     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000113395     Document Type: Article

References (37)

1. Yudkin PL, Ellison GW, Ghczzi A, Goodkin DE, Hughes RA, McPherson K, Mertin J, Milanese C: Overview of azathioprìne treatment in multiple sclerosis, Lancet 1991:338:1051-1055.
2. Salmaggi A, Corsini E, Da Mantia L, Dufur A, Eoli M, Milanese C, Nespoli A: Immunological monitoring of azathioprine treatment in multiple sclerosis patients, J Neurol 1996:244:167-174.
3. Amato MP, Pracucci G, Ponziani G, Siracusa G, Fratiglioni L, Amaducci L: Long term safety of azathioprine therapy in multiple sclerosis, Neurology 1993:43:831-833.
4. C'onfavrcux C, Saddicr P, Grimaud J, Moreau Th, Adelcine P, Aimard G: Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study, Neurology 1996:46:1607-1612.
5. Hughes RAC: Treatment of multiple sclerosis with azathioprine: in Rudick RA, Goodkin DE (eds): Treatment of Multiple Sclerosis, Trial Design, Results and Future Perspectives, Berlin, Springer, 1992, pp 157-172.
6. Kappos L, Stadt D, Ratzka M, Keil W, Schnei-dcrbanger-Grygier S, HeitzcrT, Poser S, Nadj-mi M: Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis, Neuroradiology 1988:30:299-302.
7. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, Lublin FD, Patv DW, Reingold SC, Simon J: Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis, Ann Neurol 1996:39:6-16.
8. Goodkin DE, Rudick RA, Ross JS: The use of brain magnetic resonance imaging in multiple sclerosis, Arch Neurol 1994:51:505-516.
9. Paty DW, Li DKB, Oger JJF, Kastrukol TL, Koopmans R, Tanton E, Zhao GJ: Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis, Ann Neurol 1994: 36:S95-S96.
10. Bansil S, Cook SD, Rohowsky-Kochan C: Multiple sclerosis: Immune mechanism and update on current therapies, Ann Neurol 1995: 37 (suppl 1):S87-S101.
11. Miller DH: Magnetic resonance imaging and spectroscopy in multiple sclerosis, Curr Opin Neurol 1995:8:210-215.
12. Kastrukoff LF, Oger JJ, Hashimoto SA, Sacks SL, Li DK, Palmer MR, Koopmans RA, Pet-kau AJ, Bcrkowitz J, Paty DW: Systemic lym-phoblastoid interferon therapy in chronic progressive multiple sclerosis, I, Clinical and MR1 evaluation, Neurology 1990:40:479-486.
13. Koopmans RA, Li DK, Zhao GJ: MRI assessment of cyclosporinc therapy of MS in a multicenter trial (abstract), Neurology 1992; 42 (suppl 3):210.
14. Wiles CM, Omar L, Swan AV, Sawle G, Frankel J, Grünewald R, Joannidcs T, Jones P, Laing H, Richardson PH, Hamblin AS, Harris J, Thomas G, Miller DH, Moseley IF, McDonald Wl, MacManus DG: Total lymphoid irradiation in multiple sclerosis, J Neurol Neuro-surg Psychiatry 1994;57:154-163.
15. Milligan NM, Miller DH, Compslon DAS: A placebo-controlled trial of isoprinosinc in patients with multiple sclerosis, J Neurol Neuro-surg Psychiatry 1994;57:164-168.
16. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E: C'ladribine in treatment of chronic progressive multiple sclerosis, Lancet 1994;344:9-13.
17. Paty DW, Li DKB, Ihc UBC MS/MRI Siudy Group and [he IFNB Multiple Sclerosis Study Group: Interferon beta-1 b is effective in relaps-ing-remitling multiple sclerosis, II, MRI analysis results of a multiccntcr, randomized, double-blind placebo-controlled trial, Neurology 1993;43:662-667.
18. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial, Neurology 1995: 45:1277-1285.
19. Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldmann H, Clayton D, Wing M, Scolding N, Compston A: Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis, Lancet 1994:344:298-301.
20. Ficschi C: Human recombinant intcrferon-beta in the treatment of relapsing-remitting multiple sclerosis, J Ncuroimmunol 1995;(suppl 1): 14.
21. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fisher JS, Good-kin DE, Granger CV, Simon JH, Alam JJ, Bar-toszak DM, Bourdettc DN, Braiman J, Brown-schcidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkcl RP, Mass MK, Munschaucr FE III, Priore RL, Pullicino PM, Schcrokman BJ, Wcinstock-Guttman B, Whitham RH, and the Multiple Sclerosis Collaborative Research Group (MSCRG): Intramuscular interferon beta-1 a for disease progression in relapsing multiple sclerosis, Ann Neurol 1996:39:285-294.
22. Stone LA, Frank IA, Albert PS, Bash C, Smith ME, Maloni H, McFarland H: The effect of intcrferon-b on blood-brain barrier disruption demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis, Ann Neurol 1995;37:611-619.
23. Durelli L, Bongioanni MR, Cavallo R, Ferrerò B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai S, Gcuna M, Bergamini L, Bergamasco B: Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte inter-fcron-gamma production in relapsing-remitting multiple sclerosis, Neurology 1994:44: 406-413.
24. Bastianello S, Pozzilli C, D’Andrca F, Millefio-rini E, Trojano M, Morino S, Gasperini C, Boz-zao A, Gallucci M, Andrcula C, Bozzao L, Gambi D, Prencipe M: A controlled trial of mitoxantrone in multiple sclerosis: Serial MRI evaluation at one vear, Can J Neurol Sci 1994; 21:266-270.
25. Confavreux C, Paty DW: Current status of computerization of multiple sclerosis clinical data for research in Europe and North America: The EDMUS/MS-COSTAR connection, Neurology 1995;45:573-576.
26. l4C]2-DG autoradiographs employing a general purpose image processing system, J Neurosci Methods 1984:11:243-250.
27. Paly DW, Oger JJF, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, Eisen KA, Purvcs SJ, Low MD, Brandejs V, Robertson WD, Li DKB: MRI in the diagnosis of MS: A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT, Neurology 1988:38:180-185.
28. Ormcrod IEC, Milecr DH, McDonald WI, du Boulav EPGH, Rudgc P, Kendall BE, et al: The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions, A quantitative study, Brain 1987;! 110:1579-1616.
29. Wicks DAG, Tofts PS, Miller DH, du Boulay GH, Fcinstein A, Sacares RP, Harvcv L, Brenner R, McDonald WI: Volume measurement of multiple sclerosis lesions with magnetic resonance images, Neuroradiology 1992:34:475-479.
30. Goodkin DE, Ross JS, VandcrbrugMedcndorp S, Konecsni J, Rudick RA: Magnetic resonance imaging lesion enlargement in multiple sclerosis, Disease-related activity, chance occurrence, or measurement artifact? Arch Neurol 1992;49:261-263.
31. Filippi M, Horscficld MA, Morrissey SP, Mac-Manus DG, Rudgc P, McDonald WI, Miller DH: Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis, Neurology 1994:44:635-641.
32. Smith ME, Slone MD, Albert PS, Frank JA, Martin R, Armstrong M, Maloni H, McFarlin DE, McFarland HF: Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopctctatc dimcglumine-enhancing magnetic resonance imaging lesions, Ann Neurol 1993:33:480-489.
33. Stone LA, Albert PS, Smith ME, DeCarli C, Armstrong MR, McFarlin DE, Frank JA, McFarland HF: Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis, Neurology 1995;45:1808-1814.
34. Isaacs C, Li DKB, Genton M, Jardine C, Gro-chowskj E, Palmer M, Kastrukoff LF, Ogcr J, Paty DW: Multiple sclerosis: A serial study using MRI in relapsing patients, Neurology 1988;38:1511-1515.
35. Willoughby EW, Grochowski E, Li DKB, Ogcr J, Kastrukoff LF, Paty DW: Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients, Ar.n Neurol 1989:25:43-49.
36. The IFNB Multiple Sclerosis Study Group: I, Clinical results of a multiccntcr, randomized, double-blind, placebo-controlled trial, Neurology 1993;43:655-661.
37. Koopmans RA, Li DKB, Oger JJF, Mayo J, Paty DW: The lesion of multiple sclerosis: Imaging of acute and chronic stages, Neurology 1989;39:959-963.